Tom MacDonald is Professor of Clinical Pharmacology & Pharmacoepidemiology in the Medicines Monitoring Unit, Medical School, University of Dundee and Honorary Consultant Physician at Ninewells Hospital and Medical School, Dundee His research interests include hypertension, cardiovascular disease, pharmacoepidemiology and drug safety. He is currently the Director of Tayside Medicines Monitoring Unit (MEMO) and the Hypertension Research Centre. He is also an elected member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and is the research director of the Regional Cardiovascular Risk Clinic (a European Society of Hypertension designated centre of excellence). He is currently the principal investigator of two large, multi-national, multi-centre streamlined safety studies; the Standard care versus Celecoxib Outcomes Trial (SCOT) and the Febuxostat versus Allopurinol Safety Trial) FAST. He is the Principal Investigator on the TIME study and also on the executive committee for the ALL-HEART and PATHWAY I, 2 and 3 studies. He is Past President of the British Hypertension Society, the International Society of Pharmacoepidemiology and the Pharmacovigilance Committee on Safety of Medicine.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I,Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ;British Hypertension Society's PATHWAY Studies Group. Spironolactone versusplacebo, bisoprolol, and doxazosin to determine the optimal treatment fordrug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossovertrial. Lancet. 2015 Nov 21;386(10008):2059-68. doi:10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. PubMed PMID: 26414968; PubMedCentral PMCID: PMC4655321. Pauriah M, Elder DH, Ogston S, Noman AY, Majeed A, Wyatt JC, Choy AM,Macdonald TM, Struthers AD, Lang CC. High-potency statin and ezetimibe use andmortality in survivors of an acute myocardial infarction: a population-basedstudy. Heart. 2014 Jun;100(11):867-72. doi: 10.1136/heartjnl-2013-304678. Epub2014 Feb 19. PubMed PMID: 24553389. George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association betweencardiovascular events and sodium-containing effervescent, dispersible, andsoluble drugs: nested case-control study. BMJ. 2013 Nov 26;347:f6954. doi:10.1136/bmj.f6954. PubMed PMID: 24284017; PubMed Central PMCID: PMC3898660. Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acutepancreatitis. JAMA Intern Med. 2013 Jan 28;173(2):162-4. doi:10.1001/2013.jamainternmed.477. PubMed PMID: 23183821. Wei L, Macdonald TM, Shimi SM. Appendicectomy is associated with increasedpregnancy rate: a cohort study. Ann Surg. 2012 Dec;256(6):1039-44. doi:10.1097/SLA.0b013e3182766250. PubMed PMID: 23154396. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E,Struthers AD. Improving the primary prevention of cardiovascular events by usingbiomarkers to identify individuals with silent heart disease. J Am Coll Cardiol.2012 Sep 11;60(11):960-8. doi: 10.1016/j.jacc.2012.04.049. Epub 2012 Aug 22.PubMed PMID: 22921971. Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMiccoDA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC,Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid-modifying therapies and riskof pancreatitis: a meta-analysis. JAMA. 2012 Aug 22;308(8):804-11. doi:10.1001/jama.2012.8439. PubMed PMID: 22910758. Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone andrisk of incident breast cancer in women older than 55 years: retrospective,matched cohort study. BMJ. 2012 Jul 13;345:e4447. doi: 10.1136/bmj.e4447. PubMedPMID: 22797844; PubMed Central PMCID: PMC3396460. Brown MJ, Cruickshank JK, Macdonald TM. Navigating the shoals in hypertension:discovery and guidance. BMJ. 2012 Jan 13;344:d8218. doi: 10.1136/bmj.d8218.PubMed PMID: 22246268. Wei L, MacDonald TM, Mackenzie IS. Co-prescription of co-trimoxazole andspironolactone in elderly patients. BMJ. 2011 Sep 12;343:d5656. doi:10.1136/bmj.d5656. PubMed PMID: 21911447. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and thecalcium channel blocker amlodipine combination as an initial treatment strategyfor hypertension control (ACCELERATE): a randomised, parallel-group trial.Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub2011 Jan 12. PubMed PMID: 21236483. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use andrenal toxicity: population based longitudinal analysis. BMJ. 2010 May18;340:c1768. doi: 10.1136/bmj.c1768. PubMed PMID: 20483947. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serumthyroid-stimulating hormone concentration and morbidity from cardiovasculardisease and fractures in patients on long-term thyroxine therapy. J ClinEndocrinol Metab. 2010 Jan;95(1):186-93. doi: 10.1210/jc.2009-1625. Epub 2009 Nov11. PubMed PMID: 19906785. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B,Patrick JL, Krause SL. Effects of eplerenone versus losartan in patients withlow-renin hypertension. Am Heart J. 2005 Sep;150(3):426-33. PubMed PMID:16169319. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin usein the secondary prevention of coronary heart disease in primary care: cohortstudy and comparison of inclusion and outcome with patients in randomised trials.BMJ. 2005 Apr 9;330(7495):821. Epub 2005 Mar 24. PubMed PMID: 15790616; PubMedCentral PMCID: PMC556073. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription isassociated with subsequent cardiovascular disease. Ann Intern Med. 2004 Nov16;141(10):764-70. PubMed PMID: 15545676. Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, Jung RT,Davies E, Fraser R, Connell JM. Variation at the aldosterone synthase (CYP11B2)locus contributes to hypertension in subjects with a raised aldosterone-to-reninratio. J Clin Endocrinol Metab. 2002 Sep;87(9):4398-402. PubMed PMID: 12213905.